|1.||Nishiyama, Tomoki: 9 articles (10/2006 - 11/2002)|
|2.||Silbergleit, Robert: 7 articles (08/2015 - 06/2010)|
|3.||Hirshman, Elliot: 7 articles (07/2006 - 01/2003)|
|4.||Hanaoka, Kazuo: 6 articles (12/2004 - 11/2002)|
|5.||Durkalski, Valerie: 5 articles (08/2015 - 10/2011)|
|6.||McDonough, John H: 5 articles (08/2015 - 04/2003)|
|7.||Honarmand, Azim: 5 articles (07/2015 - 02/2009)|
|8.||Rex, Douglas K: 5 articles (03/2014 - 06/2002)|
|9.||Swart, Eleonora L: 5 articles (04/2013 - 02/2004)|
|10.||Danhof, Meindert: 5 articles (08/2012 - 02/2004)|
04/01/2014 - "Most of the families (91%) found that buccal midazolam was always, or usually, effective in stopping seizures and it prevented hospital admission in 65% of cases. "
12/01/1997 - "There are limited studies that midazolam can be used successfully to treat seizures in adults and children. "
06/01/2015 - "In both models, midazolam produced rapid and dose-dependent protection against seizures (ED50, 0.4 mg/kg). "
11/01/1999 - "Since rapid seizure control minimizes the chance of brain damage, use of midazolam as an anticonvulsant may lead to improved clinical outcome in the treatment of nerve agent seizures."
11/24/2015 - "This meta-analysis of 16 studies found that intramuscular midazolam (IM-MDZ) is superior to other nonvenous medications regarding time to seizure termination after administration (2.145 minutes, 95% CrI 1.308-3.489), time to seizure cessation after arrival in the hospital (3.841 minutes, 95% CrI 2.697-5.416), and time to initiate treatment (0.779 minutes, 95% CrI 0.495-1.221). "
01/01/2013 - "This study aimed to evaluate the safety and efficacy of adjunctive midazolam during dressing changes in patients with uncontrolled pain using opioid monotherapy or significant anxiety associated with dressing changes. "
02/01/1993 - "Midazolam causes less pain on injection, a significantly greater degree of early sedation, and a more rapid return to baseline function."
11/01/2008 - "N(2)O was more effective in reducing pain compared with midazolam as measured using the Face, Legs, Activity, Cry, Consolability (FLACC) scale (p=0.010), parental estimate of pain (p=0.009), and nursing estimate of pain (p=0.007). "
04/01/1994 - "Midazolam 1 mg was effective in the males (from 45% to 10%) and tended to allay patients' pain feeling in the females (from 40% to 23%). "
11/01/1991 - "In these two cases, the addition of midazolam appeared to be effective in controlling intractable neoplastic pain."
|3.||Status Epilepticus (Complex Partial Status Epilepticus)
12/01/2006 - "To assess the efficacy of high-dose midazolam in the treatment of refractory status epilepticus in children. "
01/09/2013 - "In 2012, intramuscular midazolam appears as effective as intravenous lorezepam for the first line treatment of convulsive status epilepticus. "
03/01/2003 - "[Proposal to obtain a licensed application for midazolam (Dormicam) as a drug effective for status epilepticus]."
09/01/1999 - "Midazolam infusion, as per our described algorithm, is effective in terminating refractory status epilepticus. "
07/01/1998 - "In conclusion, midazolam infusion is an effective and safe therapeutic approach for the management of childhood status epilepticus."
|4.||Postoperative Nausea and Vomiting (PONV)
01/01/2012 - "The combination of midazolam-dexametazone is more effective than midazolam alone in prevention of postoperative vomiting after middle ear surgery. "
07/01/2015 - "Controlling for baseline differences, patients who received midazolam reported more postoperative sleepiness (P<.001) and less postoperative nausea (P=.004). "
02/01/2011 - "The incidence of postoperative vomiting was 17% with midazolam 50 µg/kg (P = .042) and 13% with midazolam 75 µg/kg (P = .019), compared with placebo (40%). "
08/01/2010 - "The difference in the incidence of PONV between patients receiving midazolam 75 μg/kg and those receiving midazolam 50 μg/kg was not statistically significant. "
07/01/2009 - "Patients in the midazolam group reported a lower incidence of total PONV, and a lower frequency of rescue antiemetic request than those in the placebo group (p < 0.05). "
|5.||Amnesia (Dissociative Amnesia)
02/01/2005 - "A significantly greater number of patients in the midazolam group graded overall tolerance as "excellent or good" (70.8% vs. 49.2%, p = 0.012) and reported a partial to complete amnesia response (52.3% vs. 32.3%, p = 0.02) when compared with the control group. "
02/22/1992 - "There was significant amnesia for material presented after drug administration, as well as for dental events and this was significantly greater for midazolam. "
01/01/1990 - "Amnesia for the immediate postoperative period was significantly greater after midazolam (P = 0.0001)."
05/01/1989 - "Midazolam produced significantly greater amnesia both at the time of induction and 30 minutes postoperatively. "
04/01/1985 - "Both drugs provided good-quality sedation, with midazolam producing a significantly greater degree of amnesia. "
|7.||Morphine (MS Contin)
|5.||Artificial Respiration (Mechanical Ventilation)